Efficacy of Daclizumab in an African-American and Hispanic renal transplant population

Herwig Ulf Meier-Kriesche, Sadanand S. Palenkar, Gary S. Friedman, Shamkant P. Mulgaonkar, Melvin V. Goldblat, Bruce Kaplan

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Current immunosuppressive regimens have decreased acute rejection rates during the 1st year after renal transplantation. However, this decrease has not been as marked in high-risk groups, such as African-American and Hispanic renal transplant recipients. We compared two simultaneous cohorts of altogether 36 African-American and Hispanic renal transplant recipients. Cohort one received a regimen of mycophenolate mofetil, prednisone, and a calcineurin inhibitor. The second cohort received the same protocol with the addition of Daclizumab (1 mg/kg for five doses given every 2 weeks). The median follow-up was 15.2 months (range 11.8-19.9 months). One patient in the Daclizumab-treated group and seven patients in the control group experienced an acute rejection episode. The rejection-free survival was significantly higher in the Daclizumab-treated group (94.4%) (66.7%, Log-rank < 0.05) at 17 months after transplantation. A Cox Proportional Hazard model revealed lack of Daclizumab therapy as the only significant risk factor for acute rejection. (hazard ratio 7.0, 95% CI = 1.1-48). The addition of the IL-2 receptor blocker Daclizumab to a triple therapy regimen may decrease early acute rejection in the high-risk groups of African-American and Hispanic patients.

Original languageEnglish (US)
Pages (from-to)142-145
Number of pages4
JournalTransplant International
Issue number2
StatePublished - Mar 2000
Externally publishedYes


  • Daclizumab
  • High-risk population
  • Immunosuppression
  • Kidney transplantation

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'Efficacy of Daclizumab in an African-American and Hispanic renal transplant population'. Together they form a unique fingerprint.

Cite this